Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.
news_6

Successful Launch of World’s first Cricket Tokens, and Launch of CricketCrazy.io: World’s First Cricket Exclusive NFT Marketplace

Cricket Foundation–World's first blockchain and crypto ecosystem dedicated to cricket–has crossed 120+ Partners, 100,000+ followers and USD200M+ marketcap on launch...

news_6

India Diabetes Devices and Drugs Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2026 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "India Diabetes Devices and Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has...

news_6

India Closed System Drug-transfer Devices Market Prospects, Trends Analysis, Market Size and Forecasts up to 2026 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "India Closed System Drug-transfer Devices Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2026" report has...

news_6

Thailand Residential and B2B Solar Rooftop Installations Markets 2021-2026: Innovation Culture in Business Models and Strategic Partnerships to Push Solar Projects Amidst Challenging Times – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Thailand Residential and B2B Solar Rooftop Installations Market, Forecast to 2026" report has been added to ResearchAndMarkets.com's offering....

news_6

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T?SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG?350A drives dose-dependent increases in...

news_6

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T?SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG?350A drives dose-dependent increases in...